Companion Animal Vaccines Market - By Vaccine Type, By Animal Type, By Route of Administration By Distribution Channel & Forecast, 2023-2032

Description

List of Tables

Global Companion Animal Vaccines Market is poised to garner sizeable gains between 2023 to 2032. The increasing pet ownership and the growing awareness of the importance of preventive healthcare in pets may drive the demand for companion animal vaccines.

Pet owners are increasingly recognizing the need to protect their furry companions from infectious diseases. Government initiatives and vaccination programs aimed at controlling and eradicating certain diseases in pets contribute to market growth. Additionally, advancements in vaccine technology, such as the development of more effective and safer vaccines, are spurring the demand for companion animal vaccines. Moreover, the rising prevalence of zoonotic diseases and the growing emphasis on animal welfare further propel the market for companion animal vaccines.

The overall companion animal vaccines market is categorized based on vaccine, animal, route of administration, distribution channel, and region.

The inactivated companion animal vaccines market is expected to record a sizeable valuation by 2032. Inactivated vaccines offer a safe and reliable method of immunization, providing protection against various infectious diseases in pets. Secondly, pet owners are increasingly prioritizing the health and well-being of their companions, leading to a greater emphasis on preventive measures like vaccinations. Additionally, advancements in vaccine technology have improved the efficacy and safety profiles of inactivated vaccines, further driving their demand in the companion animal healthcare market.

Regarding animal, the feline segment could capture a notable share of the companion animal vaccines industry by 2032. The increasing pet cat population and the rising awareness of the importance of preventive healthcare in felines are driving the sales of feline vaccines. Pet owners recognize the need to protect their cats from common infectious diseases. Additionally, advancements in vaccine development and increased availability of feline-specific vaccines are contributing to the growing demand for feline vaccines in the veterinary market.

Based on the route of administration, the market value from the oral vaccines segment could grow substantially over 2023-2032. Oral vaccines offer convenience and ease of administration, eliminating the need for injections and reducing stress in animals. Secondly, oral vaccines provide broader coverage and improved immunity response in companion animals. Additionally, these vaccines are considered safer and have fewer side effects, favoring their increased adoption in the veterinary industry.

Regionally, the Asia Pacific companion animal vaccines industry will account for a decent revenue share by 2032. There is a significant rise in pet ownership and increasing awareness of the importance of pet healthcare in the APAC region. The growing incidence of infectious diseases in companion animals has led to an increased emphasis on preventive measures like vaccination. Additionally, favorable government initiatives, improved access to veterinary care, and rising disposable income levels contribute to the growing demand for companion animal vaccines in the regional market.

Product Code: 748

Chapter 1 Methodology

1.1 Methodology & Scope
1.2 Market definition
1.3 Base estimates & calculations
1.4 Forecast parameters
1.5 COVID-19 impact analysis at global level
1.6 Data validation
1.7 Data Sources
- 1.7.1 Primary
- 1.7.2 Secondary
  - 1.7.2.1 Paid sources
  - 1.7.2.2 Public sources

Chapter 2 Executive Summary

2.1 Companion animal vaccines industry 360 degree synopsis, 2018 - 2032
2.2 Business trends
2.3 Regional trends
2.4 Vaccine type trends
2.5 Animal type trends
2.6 Route of administration trends
2.7 Distribution channel trends

Chapter 3 Companion Animal Vaccines Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing number of pet adoption
  - 3.2.1.2 Rising prevalence of zoonotic diseases
  - 3.2.1.3 Growing awareness about companion animal vaccination
  - 3.2.1.4 Increasing government initiatives for companion animal vaccination
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High cost of vaccine development
  - 3.2.2.2 Stringent regulatory scenario for vaccine development
3.3 Growth potential analysis
- 3.3.1 By vaccine type
- 3.3.2 By animal type
- 3.3.3 By route of administration
- 3.3.4 By distribution channel
3.4 COVID- 19 impact analysis
3.5 Technological advancements
3.6 Regulatory landscape
- 3.6.1 U.S.
- 3.6.2 Europe
3.7 List of core & non core vaccines by animal type
- 3.7.1 Canine
- 3.7.2 Feline
- 3.7.3 Equine
- 3.7.4 Pet Avian
3.8 Pet diseases and action mechanism
3.9 Porter's analysis
3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Companion Animal Vaccines Market Size and Forecast, By Vaccine Type (USD Million)

5.1 Key trends, by vaccine type
5.2 Live Attenuated
5.3 Inactivated
5.4 Recombinant
5.5 Others

Chapter 6 Companion Animal Vaccines Market Size and Forecast, By Animal Type (USD Million)

6.1 Key trends, by animal type
6.2 Canine
6.3 Feline
6.4 Equine
6.5 Avian

Chapter 7 Companion Animal Vaccines Market Size and Forecast, By Route of Administration (USD Million)

7.1 Key trends, by route of administration
7.2 Injection Vaccines
7.3 Oral Vaccines
7.4 Spray Vaccines

Chapter 8 Companion Animal Vaccines Market Size and Forecast, By Distribution Channel (USD Million)

8.1 Key trends, by distribution channel
8.2 Veterinary Hospital Pharmacies
8.3 Retail Pharmacy
8.4 Online Stores

Chapter 9 Companion Animal Vaccines Market Size and Forecast, By Region (USD Million)

9.1 Key trends, by region
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Poland
- 9.3.7 Sweden
- 9.3.8 The Netherlands
- 9.3.9 Rest of Europe
9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Indonesia
- 9.4.7 Philippines
- 9.4.8 Malaysia
- 9.4.9 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Columbia
- 9.5.5 Chile
- 9.5.6 Peru
- 9.5.7 Rest of Latin America
9.6 MEA
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Israel
- 9.6.5 Turkey
- 9.6.6 Iran
- 9.6.7 Rest of MEA

Chapter 10 Company Profiles

10.1 Elanco Animal Health Incorporated
10.2 Merck & Co., Inc
10.3 Boehringer Ingelheim International GmbH
10.4 Zoetis Inc.
10.5 Ceva Sante Animale
10.6 Durvet Inc.
10.7 Indian Immunologicals Ltd
10.8 Brilliant Bio Pharma
10.9 Bioveta, a.s.
10.10 Vetoquinol S.A.
10.11 Virbac